Neptune Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 3.27 M
- Company Age 35 Year, 4 Months
- Last Filing with ROC 31 Mar 1999
- Open Charges ₹ 1.55 Cr
About Neptune Drugs
Neptune Drugs Private Limited (NDPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 October 1989 and has a history of 35 years and four months. Its registered office is in Na, Gujarat.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 1999. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.27 M.
The company currently has active open charges totaling ₹1.55 Cr.
Company Details
- Location Na, Gujarat
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24231GJ1989PTC012858
-
Company No.
012858
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Oct 1989
-
Date of AGM
30 Sep 1999
-
Date of Balance Sheet
31 Mar 1999
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Neptune Drugs?
Board Members
No Directors or KMP associated with company. Upon reviewing the records, we can confirm that there are no Directors or Key Management Personnel (KMP) associated with this company at present.
Financial Performance of Neptune Drugs.
Enhance accessibility to Neptune Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neptune Drugs?
Unlock access to Neptune Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹15.50 M
₹0
Charges Breakdown by Lending Institutions
- Small Industries Development Bank Of India : 0.89 Cr
- India Sme Asset Reconstruction Company Limited : 0.49 Cr
- State Bank Of Saurashtra : 0.17 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Dec 1995 | Small Industries Development Bank Of India | ₹4.00 M | Open |
| 31 May 1995 | Small Industries Development Bank Of India | ₹4.90 M | Open |
| 13 May 1995 | India Sme Asset Reconstruction Company Limited | ₹4.90 M | Open |
| 24 Jan 1995 | State Bank Of Saurashtra | ₹1.50 M | Open |
| 07 Jul 1990 | State Bank Of Saurashtra | ₹0.20 M | Open |
How Many Employees Work at Neptune Drugs?
Unlock and access historical data on people associated with Neptune Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neptune Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neptune Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.